These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36171591)

  • 21. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.
    Park JH; Lin ML; Nishidate T; Nakamura Y; Katagiri T
    Cancer Res; 2006 Sep; 66(18):9186-95. PubMed ID: 16982762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
    Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
    Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase.
    Diao X; Yang D; Chen Y; Liu W
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC.
    Hinzman CP; Aljehane L; Brown-Clay JD; Kallakury B; Sonahara F; Goel A; Trevino J; Banerjee PP
    Carcinogenesis; 2018 Dec; 39(12):1548-1559. PubMed ID: 30165468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells.
    Nandi A; Tidwell M; Karp J; Rapoport AP
    Blood Cells Mol Dis; 2004; 32(1):240-5. PubMed ID: 14757441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
    Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
    Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
    Lee DH; Jeong YJ; Won JY; Sim HI; Park Y; Jin HS
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of TOPK/PBK in children with malignant lymphoma or reactive lymphoid hyperplasia].
    Tian X; He XL; Yuan XY; Zou RY; Zou H; You YL; Chen KK; Zhu CG
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Mar; 20(3):214-217. PubMed ID: 29530122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
    Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
    Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Protective Role of the TOPK/PBK Pathway in Myocardial Ischemia/Reperfusion and H₂O₂-Induced Injury in H9C2 Cardiomyocytes.
    Sun G; Ye N; Dai D; Chen Y; Li C; Sun Y
    Int J Mol Sci; 2016 Feb; 17(3):267. PubMed ID: 26907268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation.
    Dou X; Wei J; Sun A; Shao G; Childress C; Yang W; Lin Q
    Cancer Cell Int; 2015; 15():27. PubMed ID: 25745361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.
    Chen Z; Chen X; Zhou E; Chen G; Qian K; Wu X; Miao X; Tang Z
    PLoS One; 2014; 9(4):e95475. PubMed ID: 24743335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.
    Sicking I; Edlund K; Wesbuer E; Weyer V; Battista MJ; Lebrecht A; Solbach C; Grinberg M; Lotz J; Hoffmann G; Rahnenführer J; Hengstler JG; Schmidt M
    PLoS One; 2014; 9(10):e111306. PubMed ID: 25340395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An analysis of 68 invasive lobular breast cancer cases in clinicopathological characteristics and the prognostic determinants].
    Liu Q; Xiang HY; Ye JM; Xu L; Zhang H; Zhang S; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):119-123. PubMed ID: 29397625
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma.
    Hayashi T; Hayakawa Y; Koh M; Tomita T; Nagai S; Kashiwazaki D; Sugimori M; Origasa H; Kuroda S
    Neuropathology; 2018 Apr; 38(2):144-153. PubMed ID: 29271010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Implications of TβRII Expression in Breast Cancer.
    Gao N; Zhai Q; Li Y; Huang K; Bian D; Wang X; Liu C; Xu H; Zhang T
    PLoS One; 2015; 10(11):e0141412. PubMed ID: 26551005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
    Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
    Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
    Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
    Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.
    Huang H; Lee MH; Liu K; Dong Z; Ryoo Z; Kim MO
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.